TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06257303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frontal Plane Projection Angle
Description: Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frontal Plane Projection Angle
Description: Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.
Study: NCT06329440

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurement of diaphragm thickness
Description: Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurement of diaphragm thickness
Description: Lineer probe of the ultrasound machine will be placed sagitally on the level of 9th to 11th rib in order to observe diaphragmatic thickness change during a sniff. The thicknesses will be measured both in full expiration (Te) and full inspirium (Ti) in centimeters. The diaphragm thickness fraction will be calculated as follows: (Ti-Te)/Te
Study: NCT04923867

Intervention type: DEVICE
Intervention: Suturable DuraGen™
Description: Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Intervention type: DEVICE
Intervention: Suturable DuraGen™
Description: Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Intervention type: DEVICE
Intervention: Suturable DuraGen™
Description: Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
Study: NCT06512727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROACTIVE Intervention
Description: Duration: Once-weekly face-to-face sessions Session Time: 1.5-2 hours Intervention: (1) culturally congruent self-management (SM) education and + SM resource toolkit, (3) active prayer support, and (3) financial counseling/insurance navigation Reinforcement: daily ecological momentary intervention support using Apple smartwatches
Study: NCT05748275

Intervention type: DIAGNOSTIC_TEST
Intervention: Argos
Description: Biometry measurements first with the Argos device, then the IOLMaster 700 device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Argos
Description: Biometry measurements first with the Argos device, then the IOLMaster 700 device.
Study: NCT05991843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions of breathing
Description: Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
Study: NCT06216873

Intervention type: OTHER
Intervention: multiple trauma
Description: Review the medical record to gather the physical parameters, blood examination result and radiologic examination results
Study: NCT05333679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UTRA
Description: Collect urine on intervention participants and screen for presence of TFV.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UTRA feedback
Description: Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
Study: NCT04688502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: High intensity interval training: 6 sets x 8 bench press, 10 pull-ups, and maximal number of box jumps (each set lasting 60 sec, with 4 minutes rest between sets)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Description: 5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training
Description: 5 pull-ups, 10 push-ups, and 15 body-weight squats, repeated for 30 minutes
Study: NCT05027997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipraglurant
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipraglurant
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo tablet
Study: NCT06203366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vojta therapy
Description: Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
Study: NCT06223854

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iodized salt
Description: Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Iodized salt with lower-dose folic acid fortification
Description: Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Iodized salt with higher-dose folic acid fortification
Description: Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
Study: NCT05370001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Entotracheal tube size
Description: Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
Study: NCT05615545

Intervention type: PROCEDURE
Intervention: Cryoablation
Description: Cryoablation of selected tumor lesions
Study: NCT05721404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin Peritoneal Dialysis Solution
Description: Icodextrin (Extraneal) for long night dwell
Study: NCT05748275

Intervention type: DIAGNOSTIC_TEST
Intervention: IOLMaster 700
Description: Biometry measurements first with the IOLMaster 700 device, then the Argos device.

Intervention type: DIAGNOSTIC_TEST
Intervention: IOLMaster 700
Description: Biometry measurements first with the IOLMaster 700 device, then the Argos device.
Study: NCT06526494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral ingestion for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo for 12 weeks
Study: NCT06424366

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ballet for All Kids
Description: The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ballet for All Kids
Description: The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.
Study: NCT04197700

Intervention type: OTHER
Group type: OTHER
Intervention: Target MAP Management
Description: Target MAP Management

Intervention type: OTHER
Group type: OTHER
Intervention: Target MAP Management
Description: Target MAP Management
Study: NCT04913272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-APR2020
Description: US-APR2020 capsules 45 billion CFUs of the LBT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04441307

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Foundations
Description: Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations
Description: A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
Study: NCT05607407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Starting dose: Methimazole 15 mg/d. Six participants will receive this dose. If they achieve a 10% increase in peripheral blood H2S concentrations, an additional 13 participants will receive this dose to accrue a total of 19 participants for which a preliminary estimate of PFS6 can be calculated. If the first 6 participants do not achieve a 10% increase in peripheral blood H2S concentrations, the dose will be increased to the second and final dose level of 25 mg/d at which 19 participants will be treated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recurrent Glioblastoma Surgical Resection
Description: The purpose of resection is to remove as much tumor as possible to alleviate mass effect and to obtain brain tissue for experimental analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Assays
Description: Pharmacodynamic assays are intended to investigate drug and downstream drug-induced effects.
Study: NCT05292326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PacePress
Description: an electronically-controlled compression site which, thanks to a well-selected compression force, may contribute significantly to preventing hemorrhagic complications following electrotherapy procedures, including to increasing safety of CIED implantation procedures and accelerate wound healing significantly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard compression band
Description: standard used compression band/sand bag
Study: NCT04506853

Intervention type: DEVICE
Group type: OTHER
Intervention: MED-EL Cochlear Implant System
Description: Cochlear implant and audio processor
Study: NCT05721404

Intervention type: DRUG
Group type: OTHER
Intervention: Hypertonic Dextrose solution
Description: Hypertonic Dextrose solution for long night dwell
Study: NCT06125522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
Study: NCT06470308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reviews and Deprescribing
Description: General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria and STOPP/START criteria.
Study: NCT05318547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard-gamble technique
Description: Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: time trade-off technique
Description: Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
Study: NCT04949191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib tablets taken by mouth once daily as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib tablets taken by mouth once daily as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib tablets taken by mouth once daily as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Commercially labeled products
Study: NCT05632653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO-PCI
Description: Percutaneous coronary intervention (PCI) of a coronary chronic total occlusion (CTO) (CTO-PCI) in patients with systolic heart failure (LVEF \<50%).
Study: NCT05574322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive foot strengthening protocol
Description: This interventional group will perform the foot strengthening protocol (PRP) with physical tests as :~* Maximum muscle strength of the foot~* Foot muscle morphology

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will not perform the foot strengthening protocol and will continue with all their daily activities with no change in lifestyle.
Study: NCT04663607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of PretermConnect App
Description: Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
Study: NCT05714267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise cancelling
Description: During the operation, active noise canceling device (Sony wh100xm3) will be applied to the patients in Group-1 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive noice cancelling
Description: During the operation, passive noise canceling device (3M Peltor X5a) will be applied to the patients in Group-2 after spinal anesthesia is applied and will not be removed until the operation is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active noise cancelling with music therapy
Description: The patients in Group-3 will be given music therapy with an active noise canceling tool (Sony wh100xm3) during the surgery. The music that the patient will listen to will be left to the patient's preference. Music therapy with an active noise canceling device will be applied after spinal anesthesia is applied and will not be removed until the surgery is completed. At the end of the surgery, the trait anxiety scale will be administered to the patients and the VAS pain scale will be administered at the 1st Hour, 8th Hour and 24th Hour. The obtained data will be recorded.
Study: NCT05379088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone/zoom calls
Description: Participants will complete weekly follow-up phone/zoom calls with a member of the research team. The phone/zoom calls will typically last 30-60 minutes. Participants will discuss barriers to activity and goals for upcoming weeks.
Study: NCT04722614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Classic music hearing at amplitude approximately 60-80 dB using MP3 player connected to headphone with noise canceling property

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oil
Description: Bergamot oil inhalation through a piece of cotton gauze (2 × 2 cm square shape) with 0.5 cc of bergamot oil. It will be attached to the collar of the patient's clothes gown, approximately 15 cm below their nose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The routine intensive care unit sedation protocol
Study: NCT05901701

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level LASER therapy
Description: using semiconductor InGaAsp diode LASER type 940 nm with continuous mode of operation, with time of application 180 sec per session for 12 sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hard occlusal splint
Description: 2 mm thickness occlusal splint constructed over the maxillary arch using CAD/CAM technology.
Study: NCT05095961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 day course of oral prednisone pre-operatively. 30mg per day.
Study: NCT04211961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a 100ml infusion of saline at 4 visits during the study
Study: NCT05167851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib , a combination group of SBRT
Description: \* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib single administration group
Description: \* Lazertinib 240mg once a day(QD) oral(PO)~-If there is no disease progression or unacceptable toxicity, treatment is performed at 1 cycle (28 days) interval . This is expected to be an average of one year.
Study: NCT05829551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 1
Description: RAY1216 dose 1 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 2
Description: RAY1216 dose 2 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 3
Description: RAY1216 dose 3 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 4 &ritonavir
Description: RAY1216 dose 4 \&ritonavir or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 5
Description: RAY1216 dose 5 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 6
Description: RAY1216 dose 6 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 7
Description: RAY1216 dose 7 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 8
Description: RAY1216 dose 8 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 9
Description: RAY1216 dose 9 or Placebo with high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY1216 dose 10
Description: RAY1216 dose 10 or Placebo with high fat meal